Messaging precision becomes a commercial lever for pharma in 2026

Tern plc

The pharmaceutical sector enters 2026 facing a structural shift in how value is created and defended. A wave of patent expiries is beginning to erode revenues from established blockbusters, while a new generation of therapies prepares to compete in increasingly specialised and technically complex markets. Against this backdrop, scientific innovation remains essential but is no longer sufficient on its own. The ability to communicate that innovation clearly and convincingly to healthcare professionals is becoming a decisive commercial variable.

As legacy products approach the end of their exclusivity periods, companies are balancing short term revenue protection with the demands of launching and scaling new assets. Many of the therapies expected to drive growth in the coming decade are targeted, data rich and supported by intricate clinical narratives. These characteristics may enhance clinical value, but they also raise the bar for effective communication. Prescribers must interpret mechanisms of action, biomarker strategies and comparative evidence in a limited time frame. If messaging fails to land with clarity, adoption curves can flatten and launch investments may underperform expectations.

Artificial intelligence has been widely adopted across research and operational functions, yet its commercial application remains uneven. In 2026, the focus is shifting from experimentation to practical deployment. Tools that measure how scientific messages are understood, retained and differentiated in real world settings are increasingly viewed as essential. Rather than relying on assumptions about message recall or brand awareness, companies are seeking evidence of genuine comprehension and resonance.

Tern plc (LON:TERN) backs exciting, high growth IoT innovators in Europe. They provide support and create a genuinely collaborative environment for talented, well-motivated teams.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Talking Medicines uses AI to turn medical congress discussions into pharma insights

Talking Medicines uses AI to analyse healthcare professional conversations at medical congresses, turning discussions into structured insights that help...

Novo Nordisk deal puts focus on next generation of oral GLP-1 treatments

Novo Nordisk secures rights to Hengrui's investigational HRS-1596 in a potential $2.6bn deal, targeting the development of once-weekly oral...

Device Authority warns supermarket freezer cyberattack exposes connected device security risks

Device Authority warns that a cyberattack affecting around 700 French supermarkets exposes security weaknesses in connected industrial equipment and...

Breast cancer research highlights importance of patient intelligence in pharma

Talking Medicines highlights how AI-powered patient intelligence can help pharmaceutical companies understand breast cancer treatment experiences and identify unmet...

GLP-1 drugs linked to emerging research into mental health and addiction

Research into GLP-1 medicines is expanding beyond weight loss, with studies examining potential links to depression, cognitive function, alcohol...

Talking Medicines examines emerging links between GLP-1 drugs and mental health

Researchers are investigating the potential links between GLP-1 medicines and mental health, with early findings prompting further studies into...

Search